Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone
Drug ID BADD_D00623
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]
Marketing Status approved; investigational; vet_approved
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00292
MeSH ID D003907
PubChem ID 5743
TTD Drug ID D0IT2G
NDC Product Code 80425-0328; 0009-5019; 22552-0039; 38779-0405; 0904-7266; 55154-4901; 63187-561; 67296-1496; 70518-2998; 70868-920; 0054-4183; 0054-8176; 0054-8181; 0054-8183; 0998-0615; 55718-133; 71161-138; 79572-012; 42195-490; 45865-989; 55154-4914; 68788-8223; 70382-204; 71205-012; 42291-155; 50090-0088; 60687-718; 60687-729; 64980-509; 68788-8467; 72189-383; 55289-582; 60219-2044; 67296-0326; 0054-4179; 0054-8179; 0054-8180; 72893-015; 55718-157; 65089-0045; 42195-127; 60219-2043; 63629-7850; 70954-402; 71205-013; 0054-4181; 0054-4182; 0054-4186; 71205-703; 71879-001; 46439-8765; 82298-111; 50090-6151; 61919-827; 63187-383; 63629-4129; 63629-7806; 68788-7267; 69306-111; 69306-114; 70518-3050; 70954-404; 0054-4184; 49452-2465; 0078-0925; 0023-3348; 61919-269; 68071-2744; 68788-8293; 0054-3177; 70954-403; 0054-8175; 71335-2108; 72189-254; 51552-0430; 51927-1081; 52128-170; 42195-721; 43063-266; 48102-051; 50090-0089; 54879-003; 60219-2056; 62135-114; 68788-7142; 70954-401; 0054-8174; 72189-468; 60722-3013; 0121-1814; 42195-121; 42195-149; 42195-221; 47781-914; 47781-916; 55700-961; 69306-112; 55289-903; 63629-3742; 66993-730; 67296-1837; 68071-2321; 0054-4180; 55718-156; 57582-031; 57582-931; 42195-270; 50090-6152; 51407-361
UNII 7S5I7G3JQL
Synonyms Dexamethasone | Methylfluorprednisolone | Hexadecadrol | Decameth | Decaspray | Dexasone | Dexpak | Maxidex | Millicorten | Oradexon | Decaject | Decaject-L.A. | Decaject L.A. | Hexadrol
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 50-02-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Retinal cyst06.09.03.0220.000145%Not Available
Symptom masked08.01.03.0780.000218%Not Available
Thyrotoxic periodic paralysis17.01.04.021; 14.11.01.045; 05.02.02.0050.000145%Not Available
Vitritis06.04.06.0130.000581%Not Available
Aneurysm ruptured24.02.01.0020.000363%Not Available
Cerebral ventricle dilatation17.11.01.0130.000145%Not Available
Subclavian vein thrombosis24.01.02.0130.000145%Not Available
Live birth18.08.02.0070.001017%Not Available
Bone infarction24.04.05.011; 15.02.04.0310.000145%Not Available
Vocal cord atrophy22.04.01.0080.000392%Not Available
Hyperhomocysteinaemia14.10.02.003; 01.01.02.0210.000218%Not Available
Metastases to meninges16.22.02.003; 17.02.10.0120.000145%Not Available
Pulmonary cavitation22.01.02.0220.000291%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.000145%Not Available
Peripheral artery occlusion24.04.03.0220.000218%Not Available
Right ventricular dysfunction02.04.02.0330.000291%
Embolia cutis medicamentosa24.01.01.030; 12.07.03.052; 08.02.03.0520.000145%Not Available
Ovarian mass21.11.02.0170.000145%Not Available
Salivary gland cancer16.13.12.001; 07.21.07.0080.000218%Not Available
Renal salt-wasting syndrome20.05.03.021; 14.05.01.0110.000145%Not Available
Placenta accreta18.05.02.0030.000145%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000145%Not Available
Acute lymphocytic leukaemia recurrent16.01.01.003; 01.10.01.0030.001453%Not Available
Vitreous loss12.01.04.033; 06.09.01.0120.000785%Not Available
Necrotising retinitis06.04.06.012; 24.04.10.0060.000509%Not Available
Iris neovascularisation24.03.07.012; 06.07.06.0010.000291%Not Available
Atrophy of globe06.09.04.0070.000145%Not Available
Central nervous system leukaemia17.02.10.019; 16.01.03.004; 01.10.03.0040.000218%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000291%Not Available
Leukaemic infiltration extramedullary01.10.03.006; 16.01.03.0060.000291%Not Available
The 24th Page    First    Pre   24 25 26    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene